Fast Genetic Screening Can Identify Newborns at High Risk for Type 1 Diabetes

Researchers wanted to know whether they could quickly identify newborns at genetic risk for type 1 diabetes and enroll them in prevention studies before their immune systems begin attacking the insulin-producing cells of the pancreas. They conducted genetic screening across Belgium, Germany, Poland, Sweden, and the United Kingdom, testing more than 257,000 newborns.

The screening used polygenic risk scores—genetic tests that examine multiple DNA variants to estimate overall risk. Infants identified as having a greater than 10% chance of developing type 1 diabetes by age 6 were considered eligible for further study.

Of the 257,784 newborns tested, 3,309 (about 1.3%) carried genetic profiles indicating elevated risk for early-onset type 1 diabetes. Of these, 1,149 eligible infants were successfully enrolled in a clinical intervention study examining a probiotic supplement called Bifidobacterium infantis.

This finding suggests that genetic screening at birth could become a useful tool for identifying which children might benefit from preventive interventions before their disease process begins.

One key question was whether the entire process could happen fast enough to matter. The answer was yes. Blood samples were typically collected at 2 days of age. Genetic results reached study sites by roughly 3 weeks of life, and enrollment into the prevention study occurred around day 38 of life—well within the critical early window.

This rapid turnaround is important because early intervention, before autoimmunity develops, may be more effective than waiting until signs of immune attack are already detectable.

This study demonstrates that newborn genetic screening for type 1 diabetes risk is feasible at scale and can work across multiple countries with different healthcare systems. The screening infrastructure successfully connected high-risk infants to clinical trials testing whether early interventions might reduce their risk of developing the disease.

While genetic risk does not mean an infant will definitely develop type 1 diabetes, it identifies a group where the probability is high enough to justify enrolling them in studies of preventive approaches. This is an important step toward understanding whether early treatment can change the course of the disease.

Source: Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.